Wed.Dec 13, 2023

article thumbnail

Pfizer warns of further sales decline for COVID products, plots $500M in additional cost cuts

Fierce Pharma

Using Tuesday to announce good news—that its $43 billion acquisition of Seagen would be | Using Tuesday to announce good news—that its $43 billion acquisition of Seagen would be finalized on Thursday—Pfizer sandwiched its bad news, which came on Wednesday with its 2024 guidance. The company expects revenue to reach between $58.5 billion and $61.5 billion next year, coming up short of the analyst consensus of $63.2 billion, largely because of the plummeting demand for its COVID-19 products.

Sales 357
article thumbnail

Who Really Benefits From Medicare Advantage Plans?

MedCity News

Health systems have been increasingly dropping MA contracts, saying that they cause their organizations to lose too much money and result in dangerous patient care delays. To mitigate this issue, experts think large MA plans need to delegate more utilization management duties to health systems rather than handling it themselves.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novo Holdings' Xellia to lay off 80 workers at former Boehringer Ingelheim plant in Ohio

Fierce Pharma

After wrapping up a $200 million renovation at a former Boehringer Ingelheim plant near Cleveland, Ohio, several years back, Danish specialty drugmaker Xellia Pharmaceuticals is paring back its wor | After wrapping up a $200 million renovation at a former Boehringer Ingelheim plant near Cleveland, Ohio, several years back, Danish specialty drugmaker Xellia Pharmaceuticals is paring back its workforce in The Forest City.

article thumbnail

Report: Less than Half of Employers Are Confident In Integrity of Hospitals, PBMs

MedCity News

About eight in 10 employers think drug costs, high-cost claims and hospital prices are a “significant threat to affordability,” according to a new survey from National Alliance of Healthcare Purchaser Coalitions.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Finding that Spark

PharmExec

Lisa Conte, founder, president, and CEO of Jaguar Health, discusses how a climb up Mount Kilimanjaro would vault her to her true career calling—and spark a decades-long quest to accelerate breakthroughs in plant-based pharmaceuticals and supportive care.

article thumbnail

Google Unveils Suite of Healthcare-Specific Generative AI Models

MedCity News

Google introduced a new suite of healthcare-focused generative AI models designed to speed up workflows for clinicians and medical researchers. Health systems and medical research organizations, including HCA Healthcare and BenchSci, have been testing these models since April.

More Trending

article thumbnail

Leveraging Personalized Digital Engagement to Elevate Medicare Advantage Star Ratings

MedCity News

With the Centers for Medicare & Medicaid Services (CMS) releasing annual changes that impact all facets of the MA Star Ratings program, health systems and providers need to stay ahead of these changes and navigate them effectively by leveraging technology that can guide and optimize the complete patient journey.

Patients 109
article thumbnail

A New Era in Clinical Trials

PharmExec

Current industry challenges present an opportunity for innovation and the adoption of new solutions, particularly in addressing barriers related to patient recruitment, engagement, and retention.

article thumbnail

Challenging the ‘Growth By Any Means’ Approach in Hospital Marketing

MedCity News

When it comes to organizational growth, the concept of “growth by any means” is hurting the hospital’s bottom line and pushing healthcare to a tipping point – adding expense to American healthcare without adding value.

Marketing 105
article thumbnail

How simulations help device makers meet booming autoinjector demand

Pharmaceutical Technology

Advanced simulation methods and tools are not only paving the way for more efficient manufacturing operations. At SHL Medical, they’re also speeding up the development of new production facilities around the globe.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

A former CDC head on key R&D areas, public trust and if we learned anything from COVID-19

PharmaVoice

Dr. Julie Gerberding, now president and CEO of the Foundation for the National Institutes of Health, shares lessons learned from a long career in academic, public health and industry.

97
article thumbnail

BMS agrees $8.4bn ADC collaboration with SystImmune

European Pharmaceutical Review

Bristol Myers Squibb has entered an exclusive license and collaboration agreement for SystImmune’s BL-B01D1, a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC). As part of the potential $8.4 billion deal the companies will jointly commercialise BL-B01D1 in the United States. Bristol Myers Squibb will also assume sole responsibility for development and commercialisation of the ADC in the rest of the world, outside of Mainland China.

article thumbnail

Trade & Channel Strategies 2023: A DSCSA Update

Pharmaceutical Commerce

The seminar examines where members of the pharma supply chain stand in terms of preparation, being that the act has officially been enacted.

Pharma 105
article thumbnail

Study confirms safety of new flow-diverting stent to treat brain aneurysms

PharmaTimes

In England, ruptured brain aneurysms occur in around one in 15,000 people every year - News - PharmaTimes

Safety 116
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

AVIA Webinar Panelists Share Vision for How Health Systems Can Engage and Retain Patients [Sponsored]

MedCity News

The panelists for the digital flywheel in healthcare discussion included: Sara Vaezy of Providence; Justin Dearborn of Praia Health, Providence Digital Innovation Group; and Sonia Singh of AVIA, who served as the moderator.

article thumbnail

Eisai sets Leqembi price in Japan at a discount to US

pharmaphorum

Eisai and Biogen’s Alzheimer’s disease therapy Leqembi is due to be launched in Japan, its second market, on 20th December, and will be priced quite a lot lower there than in the US. The anti-amyloid antibody has been included in the Japan National Health Insurance (NHI) Drug Price List at just under JPY 3 million (around $20,500) per patient per year, whereas in the US its list price before discounts or rebates was set at $26,500.

Insurance 105
article thumbnail

ACSR to use digitised pathology for HIV-associated malignancies

PharmaTimes

The software has reduced the time to provide pathology data from days to hours - News - PharmaTimes

110
110
article thumbnail

Pharnext hit again as rare disease drug flunks phase 3 test

pharmaphorum

Pharnext hit again as rare disease drug flunks phase 3 test Phil.

116
116
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Pharma’s Business Case for RWE: Tapping the Full Value From These Insights

PharmExec

How drugmakers can better harness real-world evidence to drive their clinical and commercial objectives, while also providing greater clarity for healthcare providers and improved access to therapy for the patients they serve.

article thumbnail

EC approves treatment for rare haematological disorder

European Pharmaceutical Review

The European Commission has approved Blueprint Medicines’ Ayvakyt® (avapritinib) for treatment of adult patients with the haematological disorder indolent systemic mastocytosis (ISM). “Ayvakyt represents an important treatment breakthrough as the first medicine approved for patients living with ISM, and the only therapy designed to selectively target the primary genetic driver of the disease,” declared Jens Panse, Deputy Director of the Department of Haematology/Oncology of the University Hospit

article thumbnail

First and Third-Party Cookies – Privacy Implications on Paid Media

Eversana Intouch

In the dynamic realm of digital marketing, leveraging first-party and third-party cookies is akin to navigating uncharted territories. And while these data sources have long been the bedrock of digital strategies, the landscape has drastically shifted with the surge in privacy legislation. In this POV, we outline how valuable data from first-party and third-party cookies fuel your paid media strategy as well as your larger digital ecosystem.

Media 59
article thumbnail

Pfizer Clears Final Regulatory Hurdles to Acquire Seagen Inc

PharmExec

Pfizer Inc. expects to close its $43 billion acquisition of Seagen Inc., on December 14, 2023.

84
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Daiichi Sankyo taps Depixus to speed RNA drug discovery

pharmaphorum

Daiichi Sankyo taps Depixus to speed RNA drug discovery Phil.

105
105
article thumbnail

Sanofi to Terminate Rare Disease Drug Licensing Agreement with Maze Therapeutics in Wake of FTC’s Challenge

PharmaTech

Sanofi has issued a statement expressing its disappointment with FTC’s decision to block an exclusive licensing agreement with Maze Therapeutics for a rare disease drug candidate.

52
article thumbnail

Leveraging demand forecasting to make smarter healthcare investment decisions

Clarify Health

To beat the intense competition across the healthcare industry, it’s critical for providers to leverage demand forecasting to accurately forecast future healthcare utilization needs for their services and develop robust roadmaps for growth and success. For healthcare leaders, that means creating strategic plans to minimize patient leakage, relieve financial pressures, and retain and grow the patient populations they serve.

article thumbnail

Enhancing the Solubility of Active Pharmaceutical Ingredients Using Hot Melt Extrusion and Polyvinyl Alcohol (Dec 2023)

PharmaTech

Solubility of the active pharmaceutical ingredient (API) in an oral formulation is critical for absorption from the gastrointestinal (GI) tract and the intended therapeutic effect. Ensuring that an API has the necessary solubility can be challenging for drug developers and formulators. If limitations in solubility cannot be successfully addressed, a new chemical entity (NCE) is unlikely to advance in the development pipeline.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

FDA to Evaluate Application for MDMA to Become First Approved Psychedelic Drug for PTSD

Pharmaceutical Commerce

MAPS Public Benefit Corporation was previously granted Breakthrough Therapy Designation by the FDA for MDMA and is seeking a priority review for the NDA submission of the psychedelic treatment for post-traumatic stress disorder.

FDA 52
article thumbnail

MAPS Seeks Approval of First Psychedelic-Assisted Therapy for PTSD

PharmExec

MAPS Public Benefit Corporation filed a new drug application for MDMA (midomafetamine capsules) for use with psychological intervention for the treatment of post-traumatic stress disorder.

52
article thumbnail

Pfizer obtains regulatory approvals for $43bn Seagen acquisition

Pharmaceutical Technology

Pfizer has obtained all necessary regulatory approvals for concluding the acquisition of biotechnology company Seagen for $43bn in cash.

59
article thumbnail

FDA Announces Advisory Committee for Genetic Metabolic Disease Treatments

PharmaTech

The new advisory committee will provide the agency with technical and scientific advice and recommendations on potential treatments for genetic metabolic diseases.

FDA 52
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A